VTYX - Ventyx Biosciences

-

$undefined

N/A

(N/A)

Ventyx Biosciences NASDAQ:VTYX Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.

Location: 662 Encinitas Boulevard, Suite 250, CA, 92024, US | Website: ventyxbio.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-121.2M

Cash

217.3M

Avg Qtr Burn

-32.72M

Short % of Float

13.04%

Insider Ownership

4.46%

Institutional Own.

80.52%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

VTX3232 Details
Obesity and cardiometabolic risk factors

Phase 2

Data readout

Phase 2

Update

Phase 2

Update

VTX3232 Details
Parkinson's disease

Big Mover™

Susp. Mover™

Phase 2a

Data readout

VTX958 (TYK2 inhibitor) Details
Psoriatic arthritis, Psoriasis

Failed

Discontinued